Cowen analyst Eric Schmidt reiterated his Outperform rating and $494 price target on Biogen (NASDAQ: BIIB), with shares down nearly ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE